Matoba S, Tatsumi T, Keira N, Kawahara A, Akashi K, Kobara M, Asayama J, Nakagawa M
Second Department of Medicine, Kyoto Prefectural University of Medicine, Japan.
Circulation. 1999 Feb 16;99(6):817-22. doi: 10.1161/01.cir.99.6.817.
Although ACE inhibitors can protect myocardium against ischemia/reperfusion injury, the mechanisms of this effect have not yet been characterized at the cellular level. The present study was designed to examine whether an ACE inhibitor, cilazaprilat, directly protects cardiac myocytes against hypoxia/reoxygenation (H/R) injury.
Neonatal rat cardiac myocytes in primary culture were exposed to hypoxia for 5.5 hours and subsequently reoxygenated for 1 hour. Myocyte injury was determined by the release of creatine kinase (CK). Both cilazaprilat and bradykinin significantly inhibited CK release after H/R in a dose-dependent fashion and preserved myocyte ATP content during H/R, whereas CV-11974, an angiotensin II receptor antagonist, and angiotensin II did not. The protective effect of cilazaprilat was significantly inhibited by Hoe 140 (a bradykinin B2 receptor antagonist), NG-monomethyl-L-arginine monoacetate (L-NMMA) (an NO synthase inhibitor), and methylene blue (a soluble guanylate cyclase inhibitor) but not by staurosporine (a protein kinase C inhibitor), aminoguanidine (an inhibitor of inducible NO synthase), or indomethacin (a cyclooxygenase inhibitor). Cilazaprilat significantly enhanced bradykinin production in the culture media of myocytes after 5.5 hours of hypoxia but not in that of nonmyocytes. In addition, cilazaprilat markedly enhanced the cGMP content in myocytes during hypoxia, and this augmentation in cGMP could be blunted by L-NMMA and methylene blue but not by aminoguanidine.
The present study demonstrates that cilazaprilat can directly protect myocytes against H/R injury, primarily as a result of an accumulation of bradykinin and the attendant production of NO induced by constitutive NO synthase in hypoxic myocytes in an autocrine/paracrine fashion. NO modulates guanylate cyclase and cGMP synthesis in myocytes, which may contribute to the preservation of energy metabolism and cardioprotection against H/R injury.
尽管血管紧张素转换酶(ACE)抑制剂可保护心肌免受缺血/再灌注损伤,但其在细胞水平的作用机制尚未明确。本研究旨在探讨ACE抑制剂西拉普利拉是否能直接保护心肌细胞免受缺氧/复氧(H/R)损伤。
原代培养的新生大鼠心肌细胞先经历5.5小时缺氧,随后再进行1小时复氧。通过肌酸激酶(CK)释放量来测定心肌细胞损伤情况。西拉普利拉和缓激肽均能以剂量依赖方式显著抑制H/R后的CK释放,并在H/R期间维持心肌细胞的ATP含量,而血管紧张素II受体拮抗剂CV-11974和血管紧张素II则无此作用。西拉普利拉的保护作用被Hoe 140(一种缓激肽B2受体拮抗剂)、NG-单甲基-L-精氨酸单乙酸盐(L-NMMA,一种一氧化氮合酶抑制剂)和亚甲蓝(一种可溶性鸟苷酸环化酶抑制剂)显著抑制,但不受星形孢菌素(一种蛋白激酶C抑制剂)、氨基胍(一种诱导型一氧化氮合酶抑制剂)或吲哚美辛(一种环氧化酶抑制剂)影响。在缺氧5.5小时后,西拉普利拉显著增加了心肌细胞培养基中缓激肽的生成,但对非心肌细胞培养基中的缓激肽生成无此作用。此外,西拉普利拉在缺氧期间显著提高了心肌细胞中的环鸟苷酸(cGMP)含量,L-NMMA和亚甲蓝可减弱这种cGMP的增加,而氨基胍则无此作用。
本研究表明,西拉普利拉可直接保护心肌细胞免受H/R损伤,这主要是由于缺氧心肌细胞中缓激肽的积累以及组成型一氧化氮合酶以自分泌/旁分泌方式诱导产生一氧化氮(NO)所致。NO调节心肌细胞中的鸟苷酸环化酶和cGMP合成,这可能有助于维持能量代谢并对H/R损伤起到心脏保护作用。